As shown in Fig 1, 97 patients with RA who desired drug discontinuation after maintenance of remission or LDA for ≥48 weeks due to stable treatment with bDMARDs (46 patients with TNF inhibitors and 19 with tocilizumab) or tofacitinib (32 patients) were enrolled into this study. Here, TNF is linked to rheumatoid arthritis.